PURPOSE: To evaluate granulocyte colony-stimulating factor (G-CSF) efficacy in accelerating bone regeneration following opening-wedge high tibial valgus osteotomy for genu varum. METHODS: A phase II trial was conducted for evaluating the preoperative administration of G-CSF given at 10 μg/kg/day for 3 consecutive days with an additional half-dose 4 h before the opening-wedge high tibial valgus osteotomy. Overall, 12 patients (Group A) received G-CSF treatment, and the subsequent 12 patients (Group B) underwent surgery without G-CSF. The osteotomy gap was filled by a bone graft substitute. Bone marrow cell (BMC) mobilization was monitored by CD34+ve cell and clonogenic progenitor cell analysis. All patients underwent a clinical (Lysholm Knee Scale and SF-36) and radiographic evaluation preoperatively, as well as at given intervals postsurgery. RESULTS: All patients completed the treatment program without major side effects; G-CSF was well tolerated. BMC mobilization occurred in all Group A patients, with median peak values of circulating CD34+ve cells of 110/μL (range 29-256). Circulating clonogenic progenitors paralleled CD34+ve cell levels. A significant improvement in Lysholm Knee Scale was recorded at follow-up in Group A compared to Group B. At the radiographic evaluation, there was a significant increase in osseointegration at the bone-graft junction in Group A at 1, 2, 3 and 6 months postsurgery compared to Group B. The computerized tomography scan of the grafted area at 2 months postsurgery showed no significant difference in the quality of the newly formed bone between the two Groups. CONCLUSIONS: Although the limited number of patients does not allow firm conclusions, the study suggests that G-CSF can be safely administered preoperatively in subjects undergoing opening-wedge high tibial valgus osteotomy; in addition, the clinical, radiographic and CT monitoring indicate that G-CSF and/or mobilized BMCs may hasten bone graft substitute osseointegration. LEVEL OF EVIDENCE: I.
PURPOSE: To evaluate granulocyte colony-stimulating factor (G-CSF) efficacy in accelerating bone regeneration following opening-wedge high tibial valgus osteotomy for genu varum. METHODS: A phase II trial was conducted for evaluating the preoperative administration of G-CSF given at 10 μg/kg/day for 3 consecutive days with an additional half-dose 4 h before the opening-wedge high tibial valgus osteotomy. Overall, 12 patients (Group A) received G-CSF treatment, and the subsequent 12 patients (Group B) underwent surgery without G-CSF. The osteotomy gap was filled by a bone graft substitute. Bone marrow cell (BMC) mobilization was monitored by CD34+ve cell and clonogenic progenitor cell analysis. All patients underwent a clinical (Lysholm Knee Scale and SF-36) and radiographic evaluation preoperatively, as well as at given intervals postsurgery. RESULTS: All patients completed the treatment program without major side effects; G-CSF was well tolerated. BMC mobilization occurred in all Group A patients, with median peak values of circulating CD34+ve cells of 110/μL (range 29-256). Circulating clonogenic progenitors paralleled CD34+ve cell levels. A significant improvement in Lysholm Knee Scale was recorded at follow-up in Group A compared to Group B. At the radiographic evaluation, there was a significant increase in osseointegration at the bone-graft junction in Group A at 1, 2, 3 and 6 months postsurgery compared to Group B. The computerized tomography scan of the grafted area at 2 months postsurgery showed no significant difference in the quality of the newly formed bone between the two Groups. CONCLUSIONS: Although the limited number of patients does not allow firm conclusions, the study suggests that G-CSF can be safely administered preoperatively in subjects undergoing opening-wedge high tibial valgus osteotomy; in addition, the clinical, radiographic and CT monitoring indicate that G-CSF and/or mobilized BMCs may hasten bone graft substitute osseointegration. LEVEL OF EVIDENCE: I.
Authors: Mininder S Kocher; J Richard Steadman; Karen K Briggs; William I Sterett; Richard J Hawkins Journal: J Bone Joint Surg Am Date: 2004-06 Impact factor: 5.284
Authors: L de Girolamo; E Kon; G Filardo; A G Marmotti; F Soler; G M Peretti; F Vannini; H Madry; S Chubinskaya Journal: Knee Surg Sports Traumatol Arthrosc Date: 2016-04-27 Impact factor: 4.342
Authors: Jonathan S Palmer; A Paul Monk; Sally Hopewell; Lee E Bayliss; William Jackson; David J Beard; Andrew J Price Journal: Cochrane Database Syst Rev Date: 2019-07-19
Authors: Stefan Buchmann; Gunther H Sandmann; Lars Walz; Thomas Reichel; Knut Beitzel; Gabriele Wexel; Weiwei Tian; Achim Battmann; Stephan Vogt; Gerhard Winter; Andreas B Imhoff Journal: BMC Musculoskelet Disord Date: 2015-04-10 Impact factor: 2.362
Authors: A Marmotti; S Mattia; F Castoldi; A Barbero; L Mangiavini; D E Bonasia; M Bruzzone; F Dettoni; R Scurati; G M Peretti Journal: Stem Cells Int Date: 2017-11-16 Impact factor: 5.443
Authors: T Tanaka; Y Kumagae; M Chazono; S Kitasato; A Kakuta; K Marumo Journal: Knee Surg Sports Traumatol Arthrosc Date: 2014-02-05 Impact factor: 4.342
Authors: Luigi Mele; Pietro Paolo Vitiello; Virginia Tirino; Francesca Paino; Alfredo De Rosa; Davide Liccardo; Gianpaolo Papaccio; Vincenzo Desiderio Journal: Front Physiol Date: 2016-02-24 Impact factor: 4.566
Authors: Marietta Herrmann; Stephan Zeiter; Ursula Eberli; Maria Hildebrand; Karin Camenisch; Ursula Menzel; Mauro Alini; Sophie Verrier; Vincent A Stadelmann Journal: Front Bioeng Biotechnol Date: 2018-02-12